Real-time education makes headlines

Share this article:

Do physicians need a CNN for CME? Some vendors think so and are implementing real-time educational offerings.

“The doctor will not accept in their consumer life what they accept in their professional life: that the forest fire happened two months ago and they hear about it now for the first time,” said Bob Stern, CEO of breaking medical news site MedPage Today. “That's an unacceptable experience.”

The “rapid-distribution” model of presenting news from meetings or journals with credit is becoming more important as a way to meet physician needs, agreed Mario Nacinovich, Jr., co-founder/co-CEO, Fission Communications. Indeed, “some CME stakeholders are reconsidering the lengthy content development and production processes associated with traditional enduring materials,” he said.

That's not to say the traditional model is dead—far from it. According to a recent Pri-Med study, readership of one of its print CME newsletters rose 85% from 2005 to 2006. The study shows physicians still value print as a way to obtain information on new treatment options and therapies, Pri-Med's director of physician insights, Anne Goodrich, said.

Others making the immediacy push include vendors such as Epocrates, which disseminates scientific findings in lessons on handheld devices.

But MedPage Today is seriously embracing the daily news model. Its redesigned homepage contains about 12-15 stories displayed in a newspaper-like format and more standalone video stories. 
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.